Skip to content
10-Q

Quarterly Report

Zander Therapeutics, Inc

0001607062-19-000409

← back to feed
Filed
Oct 25, 2019 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2020 · Sep 30, 2019 6.58M sh
Operating Cash Flow Q1 2020 · Sep 30, 2019 −$41.6K
Cash And Equivalents Q1 2020 · Sep 30, 2019 $4.52K
Cash And Equivalents Q1 2020 · Jun 30, 2019 $28.12K
Stockholders Equity Q1 2020 · Sep 30, 2019 −$1.32M
Stockholders Equity Q1 2020 · Jun 30, 2019 $768.06K
Stockholders Equity restated Q1 2020 · Sep 30, 2018 −$585.27K
Stockholders Equity Q1 2020 · Jun 30, 2018 −$627.36K
Current Liabilities Q1 2020 · Sep 30, 2019 $2.09M
Current Liabilities Q1 2020 · Jun 30, 2019 $1.9M
Total Liabilities Q1 2020 · Sep 30, 2019 $2.09M
Total Liabilities Q1 2020 · Jun 30, 2019 $1.9M
Current Assets Q1 2020 · Sep 30, 2019 $164.57K
Current Assets Q1 2020 · Jun 30, 2019 $185.07K
Total Assets Q1 2020 · Sep 30, 2019 $767.93K
Total Assets Q1 2020 · Jun 30, 2019 $2.67M
Sga Expense Q1 2020 · Sep 30, 2019 $106.42K
Sga Expense Q1 2020 · Sep 30, 2018 $180.84K
Rd Expense Q1 2020 · Sep 30, 2019 $41.98K
Rd Expense restated Q1 2020 · Sep 30, 2018 $451.81K
Net Income Q1 2020 · Sep 30, 2019 −$2.09M
Net Income restated Q1 2020 · Sep 30, 2018 −$772.04K
Operating Income Q1 2020 · Sep 30, 2019 −$213.71K
Operating Income restated Q1 2020 · Sep 30, 2018 −$798.29K